6.83
-0.58(-7.83%)
Currency In USD
| Previous Close | 7.41 |
| Open | 7.37 |
| Day High | 7.37 |
| Day Low | 6.43 |
| 52-Week High | 9.24 |
| 52-Week Low | 2.03 |
| Volume | 745,905 |
| Average Volume | 266,304 |
| Market Cap | 361.11M |
| PE | -7.59 |
| EPS | -0.9 |
| Moving Average 50 Days | 7.5 |
| Moving Average 200 Days | 4.57 |
| Change | -0.58 |
If you invested $1000 in Sight Sciences, Inc. (SGHT) since IPO date, it would be worth $203.88 as of January 14, 2026 at a share price of $6.83. Whereas If you bought $1000 worth of Sight Sciences, Inc. (SGHT) shares 3 years ago, it would be worth $548.59 as of January 14, 2026 at a share price of $6.83.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Highlights
GlobeNewswire Inc.
Yesterday at 12:05 PM GMT
MENLO PARK, Calif., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to t
New Peer-Reviewed Publications Highlight Effectiveness of OMNI® Surgical System with TruSync™ Technology in Reducing IOP and Medication Usage in Cataract Combination Procedures, Standalone Procedures, and in African Americans
GlobeNewswire Inc.
Nov 11, 2025 12:00 PM GMT
Prospective study data and retrospective registry data were analyzed in the manuscripts recently published by the Journal of Cataract and Refractive Surgery, Journal of Glaucoma and Clinical OphthalmologyMENLO PARK, Calif., Nov. 11, 2025 (GLOBE NEW
Sight Sciences Appoints Ali Bauerlein as Chief Operating Officer and Jim Rodberg as Chief Financial Officer
GlobeNewswire Inc.
Nov 06, 2025 9:04 PM GMT
New leadership appointments strengthen Sight Sciences’ commitment to advancing our interventional dry eye initiatives and driving scalable operations and growthMENLO PARK, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT